Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion.

Anthony Joseph Esposito Jewel Imani Shikshya Shrestha Shefali Bagwe Anthony M Lamattina Marina Vivero Hilary J Goldberg Ivan O Rosas Elizabeth P Henske Souheil Youssef El-Chemaly

Published in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2023)

Our results suggest that FGF23 is associated with pulmonary diffusion abnormalities in LAM patients and elicit novel mechanisms of LAM pathogenesis. FGF23 alone or in combination with other molecules needs to be validated as a biomarker of LAM activity in future clinical research.

Keyphrases

pulmonary hypertension
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported